Le Lézard
Classified in: Health
Subjects: PDT, FDA

New FDA Cleared Balloon Catheter Used for Vessel Occlusion During Patient Resuscitation


Temporary vessel occlusion a growing practice for trauma patients.

SALT LAKE CITY, June 13, 2024 /PRNewswire/ -- Emergency Scientific, a Utah-based medical device company specializing in innovative solutions for the emergency medicine industry, has announced the first patient use of its Landmark REBOA Catheter. The Landmark Catheter was developed for resuscitative endovascular occlusion of the aorta (REBOA), a procedure developed by the military to treat hemorrhage from non-compressible fractures of the pelvis and penetrating trauma of the abdomen and has since been adopted by civilian providers.

REBOA is also used for postpartum hemorrhage (PPH), cardiac arrest (CA), abdominal aortic aneurysm (AAA) ruptures, and gastrointestinal (GI) bleeds.

"Landmark was easy to use and easy to deliver with a smooth insertion," said Scott T. Youngquist, MD, MS, FACEP, FAEMS, FAHA, an emergency medicine physician at the University of Utah who performed the first case. "REBOA can be an important tool to aid in patient resuscitation." It is estimated that more than 60,000 people die every year in the United States from traumatic hemorrhage, making it the number one cause of death in patients under 45 years old.1,2

"We are pleased to offer another solution for physicians to treat challenging emergency hemorrhage," said Ryan Murri, Emergency Scientific's Chief Executive Officer. "With high quality emergency medicine solutions, we hope to be able to save more patients suffering life threatening injuries. We believe nobody should die from the loss of blood who could be saved with the right tools, and we look forward to continuing to serve our healthcare partners with additional novel treatment options."

The Landmark REBOA Catheter recently received FDA 510(k) clearance and is indicated for temporary occlusion of large vessels including patients requiring emergency control of hemorrhage.

Emergency Scientific is a privately held company engaged in the development, manufacturing, and distribution of novel emergency medicine solutions.

  1. Latif, R.K., Clifford, S.P., Baker, J.A. et al. Traumatic hemorrhage and chain of survival. Scand J Trauma Resusc Emerg Med 31, 25 (2023). 
  2. Kauvar, David S. MD; Lefering, Rolf PhD; Wade, Charles E. PhD. Impact of Hemorrhage on Trauma Outcome: An Overview of Epidemiology, Clinical Presentations, and Therapeutic Considerations. The Journal of Trauma: Injury, Infection, and Critical Care 60(6):p S3-S11, June 2006.

SOURCE Emergency Scientific


These press releases may also interest you

at 12:07
The Women in Insurance Cancer Crusade (WICC) took another step closer to its goal of raising $25 million by 2025 at their annual Relay for Life fundraising event, held on June 6th . Nearly 300 people came together for an evening of camaraderie for...

at 12:00
"I wanted to create a simple and attractive way to secure your glasses to your shirt, jacket or other article of clothing," said an inventor, from Port St. Lucie, Fla., "so I invented the EYEGLASS PIN HOLDER. My design enables you to keep your...

at 11:56
Northwest Biotherapeutics ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024. ...

at 11:32
The American Parkinson Disease Association (APDA) is celebrating the President's signing of the National Plan to End Parkinson's Act yesterday, marking the enactment of the first-ever federal legislation dedicated to curing and preventing Parkinson's...

at 11:30
NeuroCytonix, Inc., today announced that on May 27, 2024, its subsidiary NeuroCytonix Mexico received a regulatory approval letter from the ethical, scientific, and safety committees of Hospital La Mision in Monterrey, Mexico, to launch a clinical...

at 11:00
States with high rates of COVID-19 vaccination saw more pediatric asthma patients get a break from their symptoms, according to new research published today in JAMA Network Open by leaders from Nemours Children's Health and Endeavor Health....



News published on and distributed by: